Answers are grounded in this paper and cite their sources.
In October UK patients who had cardiovascular events while taking rofecoxib lost the right to fight Merck in the US for compensation. But researchers and journals can still benefit from this case if they learn from the mistakes, write Harlan Krumholz and colleagues
No takes yet. Share an insight, caveat, or question.
Krumholz et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: